CA1341140C - Structural phosphoprotein (pp28) of human cytomegalovirus (hcmv), the preparation and use thereof - Google Patents
Structural phosphoprotein (pp28) of human cytomegalovirus (hcmv), the preparation and use thereofInfo
- Publication number
- CA1341140C CA1341140C CA000591930A CA591930A CA1341140C CA 1341140 C CA1341140 C CA 1341140C CA 000591930 A CA000591930 A CA 000591930A CA 591930 A CA591930 A CA 591930A CA 1341140 C CA1341140 C CA 1341140C
- Authority
- CA
- Canada
- Prior art keywords
- hcmv
- dna sequence
- fragment
- phosphoprotein
- human cytomegalovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 31
- 102000007982 Phosphoproteins Human genes 0.000 title claims abstract description 12
- 108010089430 Phosphoproteins Proteins 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 230000002163 immunogen Effects 0.000 abstract description 4
- 229960005486 vaccine Drugs 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Artificial Filaments (AREA)
- Safety Valves (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3805717 | 1988-02-24 | ||
| DEP3805717.4 | 1988-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1341140C true CA1341140C (en) | 2000-11-14 |
Family
ID=6348031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000591930A Expired - Lifetime CA1341140C (en) | 1988-02-24 | 1989-02-23 | Structural phosphoprotein (pp28) of human cytomegalovirus (hcmv), the preparation and use thereof |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0330051B1 (de) |
| JP (1) | JP3140019B2 (de) |
| AT (1) | ATE132533T1 (de) |
| AU (1) | AU620376B2 (de) |
| CA (1) | CA1341140C (de) |
| DE (1) | DE58909550D1 (de) |
| ES (1) | ES2081289T3 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384628A (en) * | 1992-10-10 | 1995-01-24 | Ricoh Company, Ltd. | Developing device for image forming equipment |
| AU735981B2 (en) | 1996-07-12 | 2001-07-19 | Akzo Nobel N.V. | Peptide reagent for the detection of human cytomegalovirus (CMV) |
| ATE252194T1 (de) * | 1997-08-28 | 2003-11-15 | Hunter Douglas Ind Bv | Kombinierte mehrfachverglasung und lichtsteuerungsvorrichtung |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2044881T3 (es) * | 1986-06-12 | 1994-01-16 | Behringwerke Ag | Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano. |
| DE3619902A1 (de) * | 1986-06-13 | 1988-03-03 | Biotechnolog Forschung Gmbh | Cmv-dna-strukturen, expressionsvektor dafuer, cmv-proteinstrukturen und deren verwendung |
-
1989
- 1989-02-14 DE DE58909550T patent/DE58909550D1/de not_active Expired - Lifetime
- 1989-02-14 AT AT89102503T patent/ATE132533T1/de not_active IP Right Cessation
- 1989-02-14 EP EP89102503A patent/EP0330051B1/de not_active Expired - Lifetime
- 1989-02-14 ES ES89102503T patent/ES2081289T3/es not_active Expired - Lifetime
- 1989-02-23 AU AU30244/89A patent/AU620376B2/en not_active Expired
- 1989-02-23 JP JP01045026A patent/JP3140019B2/ja not_active Expired - Lifetime
- 1989-02-23 CA CA000591930A patent/CA1341140C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE58909550D1 (de) | 1996-02-15 |
| AU620376B2 (en) | 1992-02-20 |
| ES2081289T3 (es) | 1996-03-01 |
| JPH025875A (ja) | 1990-01-10 |
| AU3024489A (en) | 1989-08-24 |
| EP0330051B1 (de) | 1996-01-03 |
| EP0330051A1 (de) | 1989-08-30 |
| JP3140019B2 (ja) | 2001-03-05 |
| ATE132533T1 (de) | 1996-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0236145B1 (de) | Verfahren zur Herstellung von HCMV-Glykoproteinen, Antikörper dagegen und HCMV-Vakzine und dazu zu verwendende rekombinante Vektoren | |
| Li et al. | The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells | |
| Fries et al. | Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients | |
| FI109604B (fi) | Diagnostinen reagenssi, joka käsittää CMV:a neutraloivan vasta-aineen kanssa reaktiokykyisen polypeptidin, sekä immunologinen määritysmenetelmä | |
| Meyer et al. | Identification and procaryotic expression of the gene coding for the highly immunogenic 28-kilodalton structural phosphoprotein (pp28) of human cytomegalovirus | |
| Yaswen et al. | Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein | |
| Wold et al. | Mapping a new gene that encodes an 11,600-molecular-weight protein in the E3 transcription unit of adenovirus 2 | |
| US6322794B1 (en) | Seroreactive epitopes on proteins of human papillomavirus (HPV) 18 | |
| JP2008188017A (ja) | エプスタイン−バールウイルスペプチド及び該ペプチドに対する抗体 | |
| Pande et al. | Human cytomegalovirus strain Towne pp65 gene: nucleotide sequence and expression in Escherichia coli | |
| JP3272641B2 (ja) | ヒトサイトメガロウィルス構造燐タンパク質の免疫原性部分、その製造および使用 | |
| US5753233A (en) | Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18 | |
| US6162620A (en) | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor | |
| CA1341140C (en) | Structural phosphoprotein (pp28) of human cytomegalovirus (hcmv), the preparation and use thereof | |
| Holden et al. | Identification and characterization of the ICP22 protein of equine herpesvirus 1 | |
| JPS62296891A (ja) | ヒトサイトメガロウィルスの主要グリコプロテイン、その製造および使用 | |
| Lund et al. | A herpesvirus saimiri protein required for interleukin-2 independence is associated with membranes of transformed T cells | |
| US6733989B1 (en) | Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof | |
| Bradshaw et al. | Localization of antigenic sites on human cytomegalovirus virion structural proteins encoded by UL48 and UL56 | |
| Desai et al. | A genetic selection method for the transfer of HSV-1 glycoprotein B mutations from plasmid to the viral genome: preliminary characterization of transdominance and entry kinetics of mutant viruses | |
| US5827519A (en) | Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use | |
| CA1340924C (en) | Structural phosphoprotein (pp 150) of human cytomegalovirus, and the preparation thereof | |
| WO1988009814A1 (en) | Expression of immunologically active proteins of human b-lymphotropic virus | |
| JP2883085B2 (ja) | Ｈｃｍｖの糖タンパク質類、それらに対する抗体類及びｈｃｍｖワクチンの産生法、並びにそれらのための組換えベクター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |
Effective date: 20171114 |